关注投资家，⭐，您会收到最新推送 作者 | 投资哥 百达信生物完成Pre-A轮融资，专注于创新疫苗佐剂研发与生产 近日，专注于创新疫苗佐剂开发与产业化的生物技术公司——重庆百达信生物技术有限公司近日宣布， 已成功完成超过3000万元人民币的Pre-A轮融资。本轮融资由领航新界资本领投。本轮所募资金将主要 用于加速公司化学合成QS-21等佐剂原料的GMP生产基地建设，推动在全球范围内的商业化进程，并进 一步拓展公司在新型佐剂领域的研发管线。（动脉网） 迈锐迪完成数千万元天使轮融资，赋能核药产业转化 近日，聚焦肿瘤与神经领域的创新企业迈锐迪宣布完成数千万元天使轮融资。本轮融资由省科创投院士 基金、西部成果转化中心、咸阳财金、国生创新、迈锐可联合投资。资金将用于精准可控高负载核药项 目开发及放射性药物中试平台建设。迈锐迪由四川大学微流控技术团队与华西医院核医学科专家联合发 起，致力于推动微流控技术在核医药领域的应用与产业化。（DoNews） 来源 | 投资家网 融资 修实生物完成近亿元A轮融资，深耕多肽生物合成领域 近日，修实生物医药（南通）有限公司宣布已完成近亿元A轮融资。本轮融资由老股东华泰紫金领投， 老股东拾 ...

Core Insights - Scientists have successfully cultivated functional neural networks in brain-like tissue without using any animal-derived materials or biological coatings, marking a significant advancement in neuropharmaceutical testing [1][2] Group 1: Technology and Methodology - The core of this technology is a novel scaffold material made from polyethylene glycol (PEG), known for its chemical inertness, which typically prevents live cells from attaching and growing without animal-derived coatings [1] - The research team utilized an innovative microfluidic technique to create a complex, interconnected porous maze structure that allows donor brain cells to recognize and utilize the inert PEG material, ultimately forming functional neural networks [1][2] Group 2: Biological Environment and Applications - The porous structure not only provides physical support for cell attachment and growth but also efficiently circulates oxygen and nutrients, creating an ideal microenvironment for cell survival, proliferation, and differentiation [2] - Once matured, the cells exhibit donor-specific neural activity, enabling the simulation and study of neurological diseases such as traumatic brain injury, stroke, or Alzheimer's disease, and allowing for direct assessment of drug efficacy and toxicity [2] Group 3: Future Plans - The current brain tissue model measures approximately two millimeters in width and is still in the preliminary stages, with plans to scale up the model to construct more complex brain region models [2] - The research team is also exploring the application of this technology to other organs, with a long-term vision of developing an interconnected organ-level culture system to simulate interactions between different organs in the human body [2]

公司将建设放射性药物中试平台，依托微流控技术在放射性药物制备过程的显著优势，为放射性药物研 发团队提供产品概念验证及CRO、CDMO等服务，包括产品概念验证、技术二次开发熟化、生物分 布、质量研究、产品评价以及核素标记等服务。平台将吸引全国乃至全球高校及科研院所核医药科技成 果转化，助力核医药产业发展。 四川省科创投董事长陈庆红表示：核医疗产业正以迅猛之势崛起，成为全球医疗健康领域的焦点。从全 球视角来看，核医疗产业正处于快速发展的黄金时期，治疗性核药已在欧美等国家上市销售，我国也有 多款肿瘤治疗的核药进入临床试验并取得进展。四川迈锐迪医疗科技有限公司是一家依托四川大学微流 控技术团队和四川大学华西医院核医学科专家团队联合发起设立的一家专注核药开发的平台型企业，通 过微流控的平台性技术，给更多的核药提供技术二次开发和成果转化。本次对迈锐迪的投资，既是对核 医疗产业发展方向的认可，更是对高校科技成果转化的持续助力。 迈锐迪医疗总经理刘承红表示：感谢各位投资人对迈锐迪的认可与支持，在当前中国核医药高速发展的 关键时期，投资人的大力支持是迈锐迪前进的重要动力。迈锐迪将依托微流控及微反应器技术搭建核素 分离与纯化技术 ...

瑞财经 刘治颖 近日，北京泰豪生物科技有限公司（以下简称"泰豪生物"）顺利完成新一轮融资，本轮 融资由善达投资管理的临沂临沭新兴产业基金独家投资。 公司在微流控芯片生产制造领域拥有独到的技术路线和经验，具备从微流控芯片设计、试剂和仪器研发 到产线建设、产品制造全链条业务能力。 天眼查显示，泰豪生物实际控制人为王磊，总持股比例为34.56%。目前，王磊担任公司董事长、经 理。 所募资金将重点用于加速公司核心产品感染性疾病微流控核酸快检试剂盒的注册申报流程，并启动现代 化生产基地的建设。 泰豪生物成立于2021年，法定代表人为王磊，注册资本为173.6万元，是一家以微流控技术为核心，围 绕生物分子检测领域开发智能快检设备，集研发、生产、销售于一体的国家高新技术企业。 ...

Core Viewpoint - The article discusses a groundbreaking study that introduces an AI-based microfluidic sperm detection and recovery system, named STAR, which successfully enabled clinical pregnancy in a male diagnosed with azoospermia, marking a significant advancement in the treatment of male infertility [3][4][8]. Group 1: Technology and Methodology - The STAR system utilizes high-power imaging technology to scan semen samples from azoospermic males, capable of capturing and analyzing millions of images in under an hour [4]. - The system combines high-speed imaging, microfluidic chips, and deep learning algorithms, processing semen at a flow rate of 400μL per hour and capturing images at 300 frames per second [4]. - A time-consistency filter enhances reliability by confirming sperm detection only if at least three out of ten consecutive frames identify sperm [4]. Group 2: Clinical Application and Results - The STAR system was applied to a couple who had been trying to conceive for nearly 20 years, with the male having undergone multiple sperm retrieval attempts with no success [7]. - Initial manual searches of the male's semen sample showed no sperm, but the STAR system identified 7 sperm (2 active) from 2.5 million images scanned [8]. - The two active sperm were successfully injected into two mature eggs, resulting in a positive pregnancy after 19 years of attempts, demonstrating the potential of AI-guided microfluidic technology in overcoming long-standing barriers in male infertility [8]. Group 3: Implications and Future Research - This breakthrough signifies a potential shift from "no hope" to "hope for parenthood" for many couples facing male infertility challenges [8]. - The research team is planning larger clinical studies to evaluate the reproducibility and effectiveness of the STAR system across a broader patient population [8].

摘要 ： 9月11日，作为BCEIA 2025同期分论坛之一，微全分析分论坛召开，论坛为期2天，首日即吸引近百人参会交流。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 仪 器 信 息 网 讯 2025 年 9 月 10 日 ， 第 二 十 一 届 北 京 分 析 测 试 学 术 报 告 会 暨 展 览 会 （ The 21s t Beijing Conference & Exhibition on Ins trumental Anal y s i s，BCEIA 2025） 在北京·中国国际展览中心（顺义馆）盛大开幕。9月11日，作为BCEIA 2025同期分论坛之一， 微全分析分论坛召开，论坛为期2天，首日即吸引近百人参会交流。 论 坛 现 场 Ka z u m a M a w a t a ri W a s e d a U n i v e r s ity 报告：AI-based Concentration Dev ice and Sensor for Microfluidics 微流控技术在化学、生物学和医学领域的超灵敏分析方面展现出 ...

Industry Overview - The exosome industry in China is experiencing strong growth, with a market size projected to reach 2.279 billion yuan in 2024, representing a year-on-year increase of 22.72% [1][7]. - Exosomes are membrane vesicles released from cells that play a crucial role in intercellular communication, containing various biomolecules such as proteins, lipids, and nucleic acids [2][6]. Industry Chain - The upstream of the exosome industry includes sources like animal, plant, and microbial exosomes, along with necessary biological reagents and production equipment [6]. - The midstream focuses on the production and manufacturing of exosomes, while the downstream applications span medical, aesthetic, and research services [6]. Key Applications - In the medical field, exosomes are utilized for tumor treatment by modulating the tumor microenvironment and delivering drugs [7]. - Exosomes serve as ideal biomarkers for liquid biopsies due to their high stability, enabling dynamic monitoring of tumor progression [7]. - In the aesthetic sector, exosomes are leveraged for anti-aging products due to their active components and low immunogenicity [7]. Market Size - The continuous advancement in biotechnology and exploration of intercellular communication mechanisms have led to significant developments in emerging technologies like engineered exosomes and microfluidics [1][11]. - The exosome market in China is projected to grow significantly, with a market size of 2.279 billion yuan expected in 2024, reflecting a 22.72% increase from the previous year [1][11]. Key Companies - Beijing Enze Kangtai Biotechnology Co., Ltd. has established a leading position in the engineered exosome sector with its GMP production facility and extensive collaborations [8]. - Guodian (Beijing) Pharmaceutical Technology Co., Ltd. focuses on innovative drug development using iPS cells and exosomes, particularly for neurological and immune-related diseases [9]. Industry Development Trends - Technological innovations are expected to enhance the efficiency and precision of exosome extraction, purification, and detection, facilitating large-scale production [11]. - The application of exosomes in disease diagnosis and treatment is anticipated to expand, with specific biomarkers being utilized for early diagnosis and therapeutic delivery [12]. - Increased government support and the establishment of industry standards will lead to stricter quality control and production practices in the exosome sector [13].

Core Viewpoint - The Chinese microfluidics industry is experiencing rapid growth, supported by favorable government policies aimed at promoting innovation and expansion among domestic companies [2][4][6]. Policy Support - A series of supportive policies have been introduced by the government to foster the development of the microfluidics industry, encouraging innovation and growth among domestic enterprises [2]. - Key policies include: - December 2023: Guidelines for establishing resource-sharing centers in county-level medical services [4]. - March 2023: Notification on centralized procurement and price management for medical consumables [4]. - May 2022: "14th Five-Year" plan promoting advanced biopharmaceuticals, including microfluidic technologies [4]. - March 2021: National economic and social development plan emphasizing disease prevention and control [4]. - February 2021: Development plan for new in vitro diagnostic equipment [4]. Market Growth - The global microfluidics market has grown from $9 billion in 2017 to $26.1 billion in 2023, with a compound annual growth rate (CAGR) of 19.42% [4]. - The Chinese microfluidics market has expanded from approximately $55.2 million in 2017 to $2.41 billion in 2023, reflecting a CAGR of about 27.84% [6]. Industry Applications - The primary application of microfluidics technology is in in vitro diagnostics, accounting for approximately 83% of its usage, with other applications including cell capture and counting [6]. Research Methodology - The research team utilized a combination of desktop research, quantitative surveys, and qualitative analysis to assess the microfluidics industry's market capacity, industry chain, operational characteristics, profitability, and business models [8].

Financial Performance - In H1 2025, the company reported revenue of 203 million yuan, a decrease of 23.91%, and a net profit attributable to shareholders of 12.4 million yuan, down 82.82% [1] - Q2 2025 revenue was 115 million yuan, a decline of 12.27%, with a net profit of 3.67 million yuan, down 88.72% [1] - The decline in revenue was primarily due to tariff impacts on U.S. business and a slowdown in government procurement, alongside decreased demand for mosquito products in Latin America and respiratory testing in domestic markets [1] Cost and Expense Analysis - The company's expense ratios for R&D, sales, management, and financial costs were 19.67%, 9.91%, 17.46%, and -6.38% respectively, with increases of 8.31, 5.67, 5.47, and 6.29 percentage points [1] - Profit margins were more adversely affected than revenue due to increased registration fees, employee stock plan costs, and reduced financial income [1] Product Development and Innovation - The company launched several new products in H1 2025, including four new drug testing reagents and a chikungunya virus testing reagent, enhancing its product pipeline [2] - Microfluidic technology has improved device portability and adaptability, achieving laboratory-level sensitivity while reducing costs by 60% [2] - The company is focusing on the development of cardiac markers, thyroid function, and nutritional products, with multi-item testing on a single chip already achieved [2] Strategic Initiatives - The company has strategically entered the brain-computer interface market through its subsidiary, investing in a company that targets treatment for severe depression [2] - The brain-computer interface market is expected to grow significantly due to policy support and technological breakthroughs, which could enhance the company's long-term growth prospects [2] Future Projections - Revenue projections for 2025-2027 are 585 million yuan, 731 million yuan, and 890 million yuan, with net profits of 108 million yuan, 166 million yuan, and 215 million yuan respectively [3] - Corresponding P/E ratios for 2025-2027 are expected to be 54.12, 35.17, and 27.27 [3]

金融界2025年8月16日消息，国家知识产权局信息显示，上海东富龙海崴生物科技有限公司取得一项名 为"一种基于微流控技术的纳米药物生产设备"的专利，授权公告号CN223221374U，申请日期为2024年 07月。 专利摘要显示，本实用新型涉及一种基于微流控技术的纳米药物生产设备，包括第一罐系统、第二罐系 统和混合系统；所述第一罐系统包括第一罐；所述第二罐系统包括第二罐；所述混合系统包括混合结 构，所述第一罐和所述第二罐共同连通所述混合结构。本实用新型的目的在于克服现有的缺陷而提供的 一种基于微流控技术的纳米药物生产设备，可以将药物充分混合，从而获得大小分布精确、包封率高的 纳米药物产品。 天眼查资料显示，上海东富龙海崴生物科技有限公司，成立于2016年，位于上海市，是一家以从事专用 设备制造业为主的企业。企业注册资本5000万人民币。通过天眼查大数据分析，上海东富龙海崴生物科 技有限公司参与招投标项目2次，财产线索方面有商标信息4条，专利信息66条，此外企业还拥有行政许 可5个。 ...